| |
MESSAGE _ENGLISH VERSION_ |
|
| |
Preclinical data on RVU602, a novel ADC payload, and the ONCO Prime
platform to be presented at the 2026 EORTC-NCI-AACR Symposium
The Management Board of Ryvu Therapeutics S.A. with its registered
office in Kraków _the "Company", "Ryvu"_ announces that the Company will
present two posters with preclinical data on RVU602, its proprietary
novel ADC payload, and on the ONCO Prime platform at the 2026
EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
_ENA_, November 18-20, 2026, Barcelona, Spain.
Details on the poster presentations are as follows:
Abstract Title: RVU602: A Non-TOP1/Non-Tubulin Cytotoxic and
Immunomodulatory Payload for Next-Generation ADCs
Abstract Number: 72
Session date and time: Wednesday, November 18 _09:00-17:00 CET_
RVU602 is a proprietary, potentially first-in-class ADC payload. Its
mechanism of action is distinct from both topoisomerase I _TOPO1_
inhibitors and microtubule inhibitors, the two payload classes on which
nearly all approved and late-stage ADCs rely. RVU602 was discovered on
Ryvu's payload discovery platform, which integrates patient-derived
models and high-throughput phenotypic screening. RVU602 disrupts an
essential intracellular survival process. It shows broad activity across
cancer cell states, including those less responsive to classical
payloads. In a subset of cell lines, it showed higher potency than DXd
_mean EC50 of 34 nM vs. 45 nM_.
RVU602 was conjugated to four antibodies: sacituzumab _anti-TROP2_,
cetuximab _anti-EGFR_, telisotuzumab _anti-c-MET_ and trastuzumab
_anti-HER2_. It formed active ADCs with all of them, reaching sub- to
low-nanomolar potency _EC50 of 0.22-14 nM in TROP2-responsive models_, a
3- to 23-fold shift versus the free payload. In TROP2 models, the
sacituzumab-RVU602 ADC matched or exceeded datopotamab deruxtecan
_Dato-DXd_. The cetuximab-RVU602 ADC was on par with a cetuximab-MMAE
comparator. The sacituzumab-RVU602 ADC was efficacious and well
tolerated in the TROP2-positive HCC70 xenograft model.
Beyond direct cytotoxicity, RVU602 induces the release of extracellular
ATP, a hallmark of immunogenic cell death, exceeding the effect of a
topoisomerase inhibitor. Together, these data confirm the activity of
RVU602 across multiple antibodies and in settings resistant to TOPO1
inhibitors. Validation of tolerability and therapeutic window is ongoing.
Abstract Title: Mapping Hidden Vulnerabilities in Genetically Stratified
Colorectal Cancer with ONCO Prime
Abstract Number: 195
Session date and time: Thursday, November 19 _09:00-17:00 CET_
Ryvu has developed a proprietary platform, ONCO Prime, to identify
actionable vulnerabilities in genetically defined cancer contexts. The
platform combines clinically relevant model systems, including healthy
human intestinal stem cells _hISCs_, engineered isogenic colorectal
cancer _CRC_ models carrying key oncogenic drivers such as APC and KRAS
alterations, and patient-derived cells _PDCs_. These models are amenable
to genetic perturbation and high-throughput pharmacological testing.
Molecular profiling, transcriptomic analyses and computational
approaches further support patient stratification and link functional
phenotypes with pathway states.
Using genome-wide CRISPR/Cas9 loss-of-function screening followed by
orthogonal validation in patient-derived CRC models, the team identified
multiple synthetic lethal _SL_ interactions associated with WNT and
RAS/MAPK pathway dysregulation. The platform enabled prioritization of
novel targets with first-in-class therapeutic potential. It also
revealed opportunities for drug repurposing of clinically advanced or
approved agents. In genetically stratified CRC models, selected
pharmacological interventions demonstrated robust in vitro activity,
including context-dependent responses and combination potential.
Together, these findings demonstrate that ONCO Prime can systematically
connect cancer genotype, pathway activity and functional vulnerability
to nominate therapeutically relevant targets. This supports the
development of both first-in-class programs and repositioning strategies
for defined CRC patient populations.
The posters will be available on the Company's website after the
presentations: https://ryvu.com/publications
Disclaimer: This English language translation has been prepared solely
for the convenience of English-speaking readers. Despite all the efforts
devoted to this translation, certain discrepancies, omissions or
approximations may exist. In case of any differences between the Polish
and the English versions, the Polish version shall prevail. Ryvu
Therapeutics S.A., its representatives and employees decline all
responsibility in this regard.
|
|
|
RB: Prezentacja danych przedklinicznych dotyczących RVU602, nowego payloadu ADC, oraz
platformy ONCO Prime podczas Sympozjum EORTC-NCI-AACR 2026 / Preclinical data on RVU602,
a novel ADC payload, and the ONCO Prime platform to be presented at the 2026 EORTC-NCI-AACR
Symposium
